← Eichor
Study identifier: NCT06679634 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Retinoblastoma Phase II Expanded Access Clinical Trial

Condition: Retinoblastoma  ·  Sponsor: Targeted Therapy Technologies, LLC

PhasePhase 2
Planned participants30
Who can joinAll sexes, N/A to 8 Years
Healthy volunteersNo

About this study

In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with retinoblastoma. The goal of the study is to further determine/assess the safety and efficacy and optimal chemotherapy dose for retinoblastoma.

This description comes directly from the study's public registry record.

Talk to the study team

Brian Marr, MD  ·  212-305-0011  ·  bpm2133@cumc.columbia.edu

Always discuss trial participation with your own doctor first.

Locations (2)

NewYork Presbyterian Morgan Stanley Children's HospitalNew York, New York, United StatesRecruiting
Children's WisconsinMilwaukee, Wisconsin, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06679634